Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

British Journal of Cancer

Volumn 101, Issue 6, 2009, Pages 998-1004

  Chua, W ^a   Goldstein, D ^b   Lee, C K ^c   Dhillon, H ^d   Michael, M ^e   Mitchell, P ^f   Clarke, S J ^a   Iacopetta, B ^g  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chemotherapy; Colorectal cancer; Metastatic; Predictive factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; EXON; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROTOXICITY; NEUTROPENIA; ONCOGENE K RAS; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENES, P53; GENOTYPE; HUMANS; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 70249135219     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605239     Document Type: Article

References (57)

1. Adamo V, Franchina T, Adamo B, Briguglio R, Restuccia E, Chiofalo G, Ferraro G, Caccamo D, Ientile R (2008) Role of MTHFR polymorphism as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: preliminary data. J Clin Oncol 26, 20 suppl abstract 15036
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type k-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634
3. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684
4. Bokemeyer C, Bondarenko I, Hartman JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P (2008) K-ras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience (abstract). J Clin Oncol 26: 18s
5. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E (2008) The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 8: 256-267
6. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, D́iaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091
7. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methlenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9: 1611-1615
8. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteǹi G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E (2005) Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'italia Meridonale. J Clin Oncol 23: 4866-4875
9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
10. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem J-L, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515
11. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750
12. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G (2004) Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal patients. Pharmacogenetics 14: 785-792
13. Etienne-Grimaldi M-C, Francoual M, Formento JL, Milano G (2007) Methylenetetrahydrofolate reductase (MTHFR) variants and fluoro-uracil-based treatments in colorectal cancer. Pharmacogenomics 8: 1561-1566
14. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz J, Milano G (2008) K-ras mutations and treatment outcomes in colorectal cancer patients receiving exclusive fluropyrimi-dine therapy. Clin Cancer Res 14: 4830-4835
15. Giachetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147
16. Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Clarke S (2005) Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 92: 832-837
17. Grieu F, Joseph D, Norman P, Iacopetta B (2004) Development of a rapid genotyping method for single nucleotide polymorphisms and its application in cancer studies. Oncol Rep 11: 501-504
18. Iacopetta B, Elsaleh H, Grieu F, Joseph D, Sterrett G, Robbins P (2000a) Routine analysis of p53 mutation in clinical breast tumour specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. Diagn Mol Pathol 9: 20-25
19. Iacopetta B, Grieu F (2000b) Routine detection of the replication error phenotype in clinical tumour specimens using fluorescence-SSCP. BioTechniques 28: 566-570
20. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23: 1365-1369
21. Jass JR (2006) Colorectal cancer: a multipathway disease. Crit Rev Oncog 12: 273-287
22. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au H-J, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefits from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765
23. Kim GP, Colangelo LH, Wieand S, Paik S, Kirsch IR, Wolmark N, Allegra C (2007) Prognostic and predictive roles of high-degree microsatellite instability in colorectal cancer: a National Cancer Institute-National urgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25: 767-772
24. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ (2009) Prognostic value of ERCC1, thymi-dylate synthase and glutathione S-transferase pi for 5-FU/ oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32: 38-43
25. Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M (2006) Methylenete-trahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57: 835-840
26. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90: 8-11
27. Marsh S, Mallon MA, Goodfellow P, Mcleod HL (2005) Concordance of pharmacogenetic markers in germline and colorectal tumour DNA. Pharmacogenomics 6: 873-877
28. Martinez-Balibrea A, Abad A, Aranda E, Sastre J, Manzano JL, Diaz-Rubio E, Gomez-Espana A, Aparicio J, Garcia T, Maestu I, Martinez-Cardus A, Gines A, Guino E, on behalf of the Spanish Group for the Treatment of Digestive Tumours (TTD Group) (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44: 1229-1237
29. McWhinney SR, Mcleod HL (2009) Using germline genotype in cancer pharmacogenomic studies. Pharmacogenomics 10: 480-493
30. Michael M, Goldstein D, Clarke SJ, Milner AD, Beale P, Friedlander M, Mitchell P (2006) Prognostic factors predictive of response and survival to a modifies FOLFOX regimen: Importance of an increased neutrophil count. Clin Colorectal Cancer 6: 297-303
31. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
32. Mitchell P, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6: 146-151
33. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G, Canzian F, and Bellvitge Colorectal Cancer Study Group (2006) Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101-2108
34. Pajak TF, Clark GM, Sargent DJ, McShane LM, Hammond EH (2000) Statistical issues in tumour marker studies. Arch Pathol Lab Med 124: 1011-1015
35. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M (2008) Pharmacogenomic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/ 5-fluorouracil as first-line chemotherapy. Br J Cancer 99: 1050-1055
36. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Gill J, Mallik N, Lenz HJ (2002) ERCC1 polymorphism is associated with differential mRNA levels. Proc Am Assoc Cancer Res 43: 321 (abstract 1591)
37. Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11: 6100-6102
38. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumour microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257
39. Royds JA, Iacopetta B (2006) p53 and disease: when the guardian angel fails. Cell Death Differ 13: 1017-1026
40. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, TP53-CRC Collaborative Study Group (2005) TP 53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumour site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518-7528
41. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenomic profiling in patients with advanced colo-rectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254
42. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8: 278-288
43. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM (2008) Five-year data and progression factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26: 5721-5727
44. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M, German 5-FU Toxicity Study Group (2008) Role of genetic and non-genetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26: 2131-2138
45. Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke S (2008) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 14: 817-825
46. Shirota Y, Stoehlmacher J, Brabender J, Xiong J-P, Uetake H, Danenberg KD, Groshen S, Tsao-Wei D, Danenberg PV, Lenz H-J (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304
47. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methlenetetrahydrofolate reductase C677T polymorphism on chemo-sensitivity of colon and breast cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144
48. Soong R, Iacopetta B (1997) A rapid and non-isotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumours. Mod Pathol 10: 252-258
49. Stoehlmacher J, Ghaderi V, Iqbal S, Groshen S, Tsao-Wei D, Park D, Lenz H-J (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21: 3075-3080
50. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H-J (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcomes to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354
51. Suh KW, Kim JH, Kim DY, Kim BY, Lee C, Choi S (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy, the MTHFR or XRCC1 gene? Ann Surg Oncol 13: 1379-1385
52. Van Cutsem E, Lang I, E'heans G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P (2008) K-ras status and efficacy in the first-line treatment of metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience (abstract). J Clin Oncol 26: 5s
53. Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S, Vaughn D, Thorn C, Whitehead AS, Haller DG, O'Dwyer PJ (2004) Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. Eur J Cancer 40: 508-514
54. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin J-C, DuCreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217
55. Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B (2003) Prognostic significance of microsatellite instability and ki-ras mutation type in stage II colorectal cancer. Oncology 64: 259-265
56. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCA) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555-560
57. Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-khoueiry A, Iqbal S, Sherrod AE, Lurje G, Lenz H (2008) Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colorectal cancer. J Clin Oncol 25: 3726-3731